World’s most innovative country clocks Agetech

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

The UN rated Switzerland the most innovative country in the world and coupled with its high life expectancy, it’s no wonder that Agetech is high on its agenda.

Longevity.Technology: As we start 2020, Longevity.Technology is looking back over some of the Longevity developments up to now and considering what’s next. We previously covered how Switzerland plans to be the new European Longevity hotspot and now with news of its number one ranking from the UN we take a look at some of the key players and developments in Longevity.

The Longevity Swiss Foundation, a Geneva-based non-profit and think-tank is aiming to turn Switzerland into a world-leading Longevity hub, calling it a new a ‘Longevity Valley’. Dmitry Kaminskiy, co-founder of the Longevity Swiss Foundation and general partner at Deep Knowledge Ventures, said: “Switzerland has a long-standing reputation as a hub for both international policy and the financial industry. The nation has extremely strong potential to leverage these existing assets in order to become the leading European hotspot for the rising Longevity financial industry.”

Sergey Young, Longevity investor and founder of the Longevity Vision Fund agrees: “The Swiss banking sector also shows a healthy interest in Longevity from an investment perspective.”

Switzerland already has a more switched-on attitude to healthcare and the oncoming ‘silver tsunami’ than most countries; compared with other European countries, Switzerland spends the highest percentage of GDP on healthcare (11.4%) and health insurance, albeit basic, is mandatory.

Although cantons organise healthcare individually, co-operation and common policies are promoted throughout the county. Co-ordinated care means a more uniform approach and better results and Spitex, a nationwide organisation, is one of the key companies providing support, health care and nursing outside hospitals and nursing homes.

CleverCare, in association with Spitex, is developing a digital platform that will enable co-ordination and communication between care staff and recipients. They are expected to launch the product early this year.

There are wearable tech developments as well; CARU has designed an intuitive smart device that is packed with sensors. Using its €2.4m in seed funding, the “digital flatmate” is suitable for care-home residents as well as those living independently. Voice-activated, it can contact professionals or family members and its on-board smart sensors monitor wellness and flag-up any deviations from learned typical behaviour.

Longevity Technology Caru
Caru, the digital flatmate for older adults (image credit: Caru)

Ovarian Longevity webinar

DomoSafety collects, correlates and analyses, in real time, data from both behavioural daily activities and medical devices. Data from multiple sources is aggregated and passed to healthcare professionals who can then deliver preventive and proactive services to their patients. Boasting over 225,000 days of analysed data, the self-learning technology allows medical detection from a distance, as well as monitoring for chronic diseases and abnormal behaviour.

Big Pharma Swiss multinational Novartis has several Longevity irons in the fire; from collaborating with Amazon Web Service to improve medicine manufacture and delivery, to developing drugs that will treat diseases related to immunosenescence and from improving the health and Longevity of transplanted organs by treating them with an experimental compound called iscalimab to identifying biomarkers for resistance to Alzheimer’s disease and cognitive decline, Novartis are throwing considerable weight behind anti-aging research.

Swiss company Amazentis, in conjunction with the Swiss Institute of Bioinformatics has discovered that a substance originating fruits, especially pomegranates, Urolithin A, can have a beneficial effect on mitochondrial function which results in the slowing of certain aging processes. Nestlé Health Science has announced it is going into partnership with Amazentis to develop off-the-shelf products containing Urolithin A.

Prexton Therapeutics is a Swiss company developing innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other degenerative brain disorders. Designing new metabotropic glutamate receptor mGluR4 compounds they hope to slow, or even arrest, the progress of these debilitating diseases.

Swiss company Roche, another Big Pharma, is developing personalised healthcare and genomics by providing comprehensive genomic profiling (CGP), a specific type of genomic testing. CGP is able to provide a more detailed picture of a cancer tumour by looking for multiple mutations in a large number of cancer-related genes and allow clinicians to provide targeted treatments that are specific to the patient and much more likely to succeed.

GenomSys develops technology that allows fast and efficient processing and sharing of DNA data. This in turn enables large scale use of DNA data for diagnostics, pharmacogenomics and personalised genomic medicine. Series A funding raised CHF9.3M last year.

Ovarian Longevity webinar

As Margaretta Colangelo, Co-Founder and Managing Partner at Deep Knowledge Ventures and Longevity Capital, said: “Switzerland is one of the most longevity progressive countries in the world … [that] has the potential to be a world leader in both the Global Longevity Industry and the 4th Industrial Revolution … Switzerland is in an excellent position to retain its leading position by focusing on the optimal assembly of its existing resources to transform the challenge of demographic aging into a national asset [3].”

[1] https://news.un.org/en/story/2019/07/1043151
[2] http://www.oecdbetterlifeindex.org/countries/switzerland/
[3] https://www.forbes.com/sites/cognitiveworld/2019/12/07/ai-will-drive-the-multi-trillion-dollar-longevity-economy

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

SENS spin-out Underdog closes $10m financing round

Underdog Pharmaceuticals, a key investment of rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Michael Greve’s Kizoo Technology Capital Group led the...

Unlocking ovarian aging could prolong fertility and delay menopause

Ovarian aging is poorly understood, under-researched and under-invested. We need a radical rethink of how we address fertility and the menopause – it's time...

Occuity raises over £2.5m for optical diabetes devices

UK MedTech firm Occuity successfully raises over £2.5m to deliver ophthalmic and optical diabetes devices and is now overfunding on Seedrs to accelerate development. DISCLOSURE:...
Nutriop